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Abstract
Background: Intensity-modulated proton therapy (IMPT), non-coplanar 4π intensity-modulated radiation therapy
(IMRT), and volumetric-modulated arc therapy (VMAT) represent the most advanced treatment methods based on
heavy ion and X-rays, respectively. Here we compare their performance for prostate cancer treatment.
Methods: Ten prostate patients were planned using IMPT with robustness optimization, VMAT, and 4π to an initial
dose of 54 Gy to a clinical target volume (CTV) that encompassed the prostate and seminal vesicles, then a boost
prescription dose of 25.2 Gy to the prostate for a total dose of 79.2 Gy. The IMPT plans utilized two coplanar,
oblique scanning beams 10° posterior of the lateral beam positions. Range uncertainties were taken into
consideration in the IMPT plans. VMAT plans used two full, coplanar arcs to ensure sufficient PTV coverage. 4π plans
were created by inversely selecting and optimizing 30 beams from 1162 candidate non-coplanar beams using a
greedy column generation algorithm. CTV doses, bladder and rectum dose volumes (V40, V45, V60, V65, V70, V75,
and V80), R100, R50, R10, and CTV homogeneity index (D95/D5) were evaluated.
Results: Compared to IMPT, 4π resulted in lower anterior rectal wall mean dose as well as lower rectum V40, V45,
V60, V65, V70, and V75. Due to the opposing beam arrangement, IMPT resulted in significantly (p < 0.05) greater
femoral head doses. However, IMPT plans had significantly lower bladder, rectum, and anterior rectal wall max dose.
IMPT doses were also significantly more homogeneous than 4π and VMAT doses.
Conclusion: Compared to the VMAT and 4π plans, IMPT treatment plans are superior in CTV homogeneity and
maximum point organ-at-risk (OAR) doses with the exception of femur heads. IMPT is inferior in rectum and
bladder volumes receiving intermediate to high doses, particularly to the 4π plans, but significantly reduced low
dose spillage and integral dose, which are correlated to secondary cancer for patients with expected long survival.
The dosimetric benefits of 4π plans over VMAT are consistent with the previous publication.
Keywords: Prostate cancer, 4π radiotherapy, Intensity modulated proton therapy, Volumetric modulated arc
therapy
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Background
It is estimated that in the year 2015, there will be around
220,800 new cases of prostate cancer and around 27,540
deaths. Prostate cancer is the second most common can-
cer and the second leading cause of cancer death for
men in the United States [1]. External beam radiation
therapy is commonly used to treat prostate cancer. Studies
have shown the benefits of 76 Gy or higher conventionally
fractionated treatments, although there is a substantial
risk of gastrointestinal toxicity, particularly stemming
from the rectum dose [2, 3]. In these cases, radiation doses
better conforming to the prostate are necessary to reduce
possible rectal complications.
The use of charged particle beams, such as proton,
demonstrates strong potential for highly conformal dose
distribution. The Bragg peaks of proton beams allow ex-
tremely localized dose delivery at a precise depth with
no exit dose after the distal tail and secondary particles.
However, since most targets are larger than the Bragg
peaks, a Spread-Out-Bragg-Peak (SOBP) must be created
to homogeneously cover the target laterally and in the
beam direction. A range-shifter wheel is typically used to
modulate the incident proton energy for varying depths.
The proton beams are further broadened by high-Z scat-
ter foils and then collimated to the size of the target. To
compensate for the surface contour of the patient, tissue
composition and shape of the target, a custom compen-
sator is made for each patient. With these additional de-
vices, passive scattering delivers a number of individual
Bragg peaks of different depths and weighted to achieve
the SOBP. Although this technique has attracted world-
wide interest, it is considered a simple method with con-
siderable limitations [4] including low dose conformity,
secondary particles including neutrons that increase pa-
tient integral dose and the logistic hurdles associated
with devices needed for individual patients.
Active scanning is a development that can be automat-
ically controlled, allowing proton beams to achieve a
more efficient complete dose delivery [5]. To cover a tar-
get, each beam is scanned laterally across the target
using magnetic fields in a technique called Pencil Beam
Scanning (PBS) [6]. PBS enables state of the art intensity
modulated proton therapy (IMPT), which is analogous
to the intensity modulated radiation therapy (IMRT) that
inversely optimize all beams to deliver a uniform dose
to the target while individual beams only deliver a partial
heterogeneous dose [7].
For photon therapy, Volumetric Modulated Arc Therapy
(VMAT) is a widely adopted technique with advantages
over conventional step-and-shoot Intensity-Modulated
Radiation Therapy (IMRT), namely its delivery efficiency
at equivalent dosimetry [8–10]. VMAT is unable to
achieve the organ-at-risk (OAR) dose sparing demon-
strated by proton therapy due to proton’s advantageous
Bragg peaks [11–13]. However, photon therapy has the
advantage of being a much more cost effective and wide-
spread treatment modality. 4π radiotherapy is a non-
coplanar IMRT technique that has demonstrated superior
OAR dose sparing compared to VMAT in various tumor
sites, including the prostate [14–18]. There is an increas-
ing interest in comparing the non-coplanar 4π treatment
to the state-of-the-art proton prostate therapy for relative
dosimetric benefit. Here, we study the dosimetric per-
formance of IMPT proton compared to photon VMAT
and 4π therapy for prostate cancer.
Methods
Patients
This retrospective study was approved by the Internal
Review Board of the Willis-Knighton Health System.
Ten prostate patients were selected, each with an initial
dose of 54 Gy to a clinical target volume (CTV) encom-
passing the prostate and seminal vesicles, then a boost
of 25.2 Gy to a CTV encompassing only the prostate for
a total dose of 79.2 Gy delivered in fractions of 1.8 Gy.
The patients were then planned using the IMPT tech-
nique described as follows.
IMPT planning
The treatment plans for the ten patients were generated
with the IBA ProteusOne compact system beam model
on the RayStation researh version 4.99.1 (RaySearch La-
boratories, Stockholm, Sweden) with automatic spot spa-
cing and spot placing. IMPT plans used two coplanar,
oblique beams angled 10° posterior of the lateral beam
positions. A pencil beam algorithm was used for proton
dose calculation with 3 × 3 × 3 mm3 dose grid. The IBA
ProteusOne compact gantry with C230 cyclotron has a
70–226 MeV energy range. The spot size in air is
3.5 mm at the max energy and 7.6 mm at the lowest en-
ergy. Spot size variation with gantry angle is less than
5%. A maximum of 0.5 cm uniform setup error and a
range uncertainty of 3.5% were used in the robustness
setting for optimization. Since the concept of PTV was
Table 1 Structure dose constraints used for IMPT, 4π, and VMAT
planning
Structure Objectives
PTV 100% of Rx to 100% of CTV
Bladder V70 < 20%
V40 < 60%; V45 < 50%; V60
< 40%; V70 < 20%; V75.6 <
Rectum 10%; V78–80 < 5%
Femoral heads V45 < 50%; max dose < 50Gy
Sigmoid colon max dose < 50Gy
Small bowel max dose < 50Gy
Anterior rectal wall V70 < 40%
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not used in IMPT, dosimetric analysis of the target was
focused on the clinical target volume (CTV). The dose
objectives used for all treatment plans are shown in
Table 1, with the CTV dose normalized at 100% of pre-
scription dose delivered to 100% of the volume.
VMAT planning
The IMPT treatments were re-planned using VMAT
(RapidArc, Eclipse Treatment Planning System version
13, Varian) with 2.5 × 2.5 × 2.5 mm3 dose grid. Both
photon treatments used the PTVs for planning but then
normalized to the CTV to be consistent with the IMPT
plans. For the X-ray plans, these PTVs have a 5 mm pos-
terior margin and 6 mm in all other directions. Each
plan used two full coplanar arcs to ensure good PTV
coverage. To match the proton plan target coverage,
VMAT plans were normalized for 100% of the prescrip-
tion dose covering 100% of the CTVs. With this primary
prescription satisfied, on average, 97.3% of PTV is cov-
ered by 100% of the prescription dose. The collimator
was rotated 90° between the arcs. Optimization objec-
tives for VMAT planning were the same constraints
used in IMPT planning (Table 1) or lower, if possible,
for normal tissues. PTV hot spots were constrained to
be as low as possible.
4π radiotherapy
4π radiotherapy was developed to incorporate non-
coplanar beams distributed on the 4π spherical surface,
thus the name, in IMRT optimization. 4π optimization
begins with a candidate pool of 1162 non-coplanar
beams, each 6° apart in the 4π solid angle space. Using a
computer assisted design (CAD) model of the Varian
TrueBeam machine and a 3D human surface model,
each angle is simulated and subsequently eliminated if a
collision is predicted between the gantry and the couch
or patient [19]. The remaining beams were divided into
5 × 5 mm2 beamlets, whose dose was calculated using con-
volution/superposition and Monte Carlo calculated 6MV
polyenergetic kernels as described previously [20, 21]. The
dose calculation resolution is 2.5 × 2.5 × 2.5 mm3. Inverse
optimization is performed by using a greedy column gener-
ation algorithm to iteratively select 30 non-coplanar beams
with integrated fluence map optimization [22]. The 30
Fig. 1 Isodose colorwash of a typical patient planned using IMPT, 4π, and VMAT plans
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beam angles consisted of 24–30 couch kicks for
the 10 patients. The beam angles were then
imported into Eclipse to recalculate the IMRT
dose, creating a clinically deliverable plan that can
be directly compared to the IMPT and VMAT
plans. The 4π optimization objectives used in
Eclipse were identical to VMAT constraints as de-
scribed above, including normalization for the CTV
dose. On average, 99.3% of PTV is covered by
100% of the prescription dose.
Fig. 2 DVH of an example case for IMPT, 4π, and VMAT plans. A = anterior rectal wall, B = bladder, C1 = CTV 1, C2 = CTV 2, E = external, LF = left
femoral head, RF = right femoral head, R = rectum, S = sigmoid, SB = small bowel
Fig. 3 Box and dot plots of OAR mean and max doses. *p < 0.05
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Dose comparison
Various dose metrics were evaluated for comparison of
the IMPT, VMAT, and 4π plans. Table 1 lists the plan-
ning objectives used for all treatment planning methods.
Metrics used for planning objectives were calculated and
compared between planning techniques, including V40,
V45, V60, V70, V75.6, V80 of the rectum, V70 of the
bladder, mean, and max doses for organs at risk. Multi-
variate regression was performed on these OAR metrics
to determine the influence of the OAR volume. Because
the concept of PTV is no longer used in IMPT pros-
tate planning, CTV coverage was compared using
mean, max doses, and CTV homogeneity index,
which was evaluated by calculating the D95 to D5 ra-
tio. R50 and R10, which were defined as the 50 and
10% isodose volume to evaluation CTV ratios, were
also calculated to examine high dose and low dose
spillage, respectively. Since PTV was not used in the
IMPT plans, the standard conformity index of the ra-
tio between the 100% isodose volume and the PTV
did not apply. Instead, to quantify the 100% isodose
volume, we calculated R100, which is the ratio be-
tween 100% isodose volume and the CTV.
Results
Isodose and dose volume histogram (DVH) comparisons
between the three treatment modalities for a representa-
tive example case are shown in Figs. 1 and 2. As one
would expect, the lateral beam angles used by the IMPT
plans delivered substantially greater dose to the femoral
heads than photon plans delivering beams from vastly
more beam orientations. It is also worth to note the ob-
lique dose distribution patterns resulted from 4π non-
coplanar beams, in comparison to the coplanar VMAT
and proton plans. Subsequently, the 4π femoral head
doses are also significantly lower than those of VMAT.
However, IMPT resulted in more homogeneous CTV
coverage, reducing the hot spots visible in the 4π and
VMAT dose in Fig. 1 as well as the CTV DVHs in Fig. 2.
The OAR and CTV dose metrics are shown in Figs. 3,
4, and 5 as boxplots for each patient overlaid with box-
plots summarizing the data. The central colored line of
the boxplots represents the median, with the edges
representing the 25th and 75th percentiles. The whiskers
show the range of data excluding outliers. The central,
dashed black line represents the mean. Wilcoxon signed
rank tests were performed between each pair of
Fig. 4 Box and dot plots of bladder and rectum dose volume metrics. *p < 0.05
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treatment modalities. Significant differences (p < 0.05)
between treatment modalities are annotated in Figs. 3, 4,
and 5 with asterisks.
Mean doses of the bladder and sigmoid colon and max
doses for the bladder, rectum, and anterior rectal wall
were lowest with IMPT planning. 4π had the lowest
mean dose for the anterior rectal wall and the femoral
heads and the lowest max dose for the femoral heads.
VMAT did not outperform both 4π and IMPT in any
OAR mean or max dose (Fig. 3). Of the specific dose
metric constraints for the bladder, VMAT had the lowest
V70 and V75. 4π achieved the lowest dose volumes for
all rectum metrics except for V80 (Fig. 4). IMPT is su-
perior in almost all of the CTV dose metrics, showing
more homogeneous dose distribution in the CTV. IMPT
had the least intermediate and low dose spillage (R50
and R10), as well as integral dose. However, the 100%
isodose volume was lowest with VMAT plans.
Figure 6 shows the results of the multivariate regres-
sion analysis for dose metrics and OAR volumes. Rec-
tum V40 increases with increasing rectum volume for all
three techniques but it appears to increase more with
IMPT than the X-ray counter parts. However, rectum
V80 of IMPT increases slower than that of VMAT and
4π. As expected, the average bladder doses decrease for
all three planning methods but the maximum doses also
decrease with increasing bladder volume.
Discussion
Proton therapy is attractive due to the unique physical
properties of the heavy charged particles that deliver the
majority of dose in sharp Bragg peaks and leave no exit
dose. On the other hand, the side by side dosimetric com-
parison between proton therapy and the best of photon
therapy has rarely been performed. In a dosimetric com-
parison between 3D conformal proton therapy (CPT) and
IMRT, Trofimov et al. concluded that IMRT resulted in
superior bladder sparing and similar rectum sparing com-
pared to 3D CPT, which is superior in reducing the low
dose spillage [23]. The same study also pointed out that
the lack of dose conformity in 3D CPT would be over-
come with the use of scanning pencil beam and intensity
Fig. 5 Box and dot plots of CTV metrics. *p < 0.05
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modulated proton therapy (IMPT). With the improve-
ment of proton therapy techniques, PBS proton has grad-
ually replaced passive scatter due to its superior dose
shaping capability. In our comparison, state of the art PBS
based IMPT was used.
At the same time, VMAT has evolved to be the mainstay
therapy method for the prostate because of good dosim-
etry quality and superior delivery efficiency, compared to
static beam IMRT. There has been a notion that VMAT
may be the ultimate IMRT method for the prostate [24]
and static beam IMRT will be completely phased out. 4π
radiotherapy revived non-coplanar IMRT methods by pro-
viding a mathematical tool for combined beam orientation
and fluence map optimization. This method was shown to
be advantageous to coplanar VMAT for almost all disease
sites including the prostate and yet is deliverable on exist-
ing C-arm linacs. In light of the technical improvement in
both photon and proton techniques, revisiting the dosi-
metric comparison provides interesting insight to the
treatment modality selection problem.
In our study, IMPT generally achieved similar dose
sparing overall compared to the photon treatment
methods, with the exception of the high doses to the
femoral heads, due to proton entrance dose. Compared
to the photon plans, IMPT is clearly better in PTV dose
homogeneity and coverage. It also reduced maximal
doses to the bladder, rectum, and anterior rectal wall.
However, the advantage disappears when OAR volumes
receiving high dose are considered. This is due to several
factors. The most important one can be seen in Fig. 1,
that the concave CTV is lateral to the anterior portion of
the rectum, placing this volume along the proton beam
direction and subject it to the increased distal penumbra
dose. The second factor contributing to the rectum and
bladder dose is the proton spot sizes ranging from 3.5 to
7.6 mm, creating less sharp beam edges in the directions
perpendicular to the beams. Variable spot spacing may re-
duce the spot size related penumbra but has not been im-
plemented in commercial planning systems.
The multivariate analysis shows that the magnitude of
difference in dosimetric metrics of treatment modalities
may depend on the OAR volume but not the relative re-
lationships. For instance, the relative disadvantages and
advantages of IMPT for V40 and V80, respectively,
widen for larger rectum volumes. This information may
be used to steer patient treatment if confirmed with a
larger patient cohort. The bladder mean dose decreasing
with increasing bladder volumes is intuitive. However,
the similar decrease in the bladder maximum dose is less
intuitive. It is possibly due to the distance between the
bladder and the CTV also increasing with increasing
bladder volume.
Fig. 6 Multivariate regression analysis on rectum V40, rectum V80, bladder mean, and bladder max dose
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Between the two photon techniques, 4π plans are su-
perior to VMAT plans with the exception of sigmoid
colon dose and small differences in the maximum point
doses to the bladder and rectum. The increase in dose
to the sigmoid colon in the 4π plans is a result of non-
coplanar beams delivering dose to superior and inferior
structures. However, the off-plane dose is low and less of
a concern in prostate treatment. This is consistent with
previous studies comparing VMAT to 4π for a different
prostate stereotactic body radiotherapy patient cohort
[17]. Putting all three modalities together, one may make
the observation that IMPT excels at reducing the max-
imal point dose to surrounding normal organs, reducing
the low dose spillage and achieving a more homoge-
neous target dose. 4π improves the intermediate dose
spillage compared to VMAT and achieves the lowest rec-
tum volume receiving 40–70 Gy.
Different from the higher cost of proton, 4π delivery does
not require new expensive equipment. Instead, it requires
more sophisticated geometrical modeling to prevent
gantry-patient collision. The delivery time of 4π plans in-
volving a large number of beams can be excessively long in
the manual mode. This limitation will be overcome using
automating non-coplanar plan delivery [19].
Conclusion
In comparison to coplanar VMAT and non-coplanar 4π
plans for the prostate treatment, IMPT proton treatment
plans showed benefits in integral dose, CTV coverage,
homogeneity and maximum point OAR doses. IMPT is
inferior in rectum and bladder volumes receiving inter-
mediate to high doses, particularly to the 4π plans. The
dosimetric benefits of 4π plans over VMAT are consist-
ent with the previous publication. Specifically, increasing
the organ weights of the rectum and bladder forces the
plan to use more non-coplanar beams to move dose to
the inferior and superior planes while similar increase in
the coplanar VMAT plans was ineffective.
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